Drug
ALK Diluent
ALK Diluent is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
4
80%
Ph phase_1
1
20%
Phase Distribution
1
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (20.0%)
Phase 24 (80.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass
NCT04296474
completedphase_2
Intralymphatic Immunotherapy in Increasing Doses, Substudy
NCT02975479
completedphase_2
Is Intralymphatic Allergen Immunotherapy Effective and Safe?
NCT04210193
completedphase_2
Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy
NCT02679105
completedphase_2
Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy
NCT02423707
Clinical Trials (5)
Showing 5 of 5 trials
NCT04296474Phase 1
Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass
NCT02975479Phase 2
Intralymphatic Immunotherapy in Increasing Doses, Substudy
NCT04210193Phase 2
Is Intralymphatic Allergen Immunotherapy Effective and Safe?
NCT02679105Phase 2
Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy
NCT02423707Phase 2
Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5